CA 19-9 in serum and pancreatic juice: Its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis

A. Malesci, A. Evangelista, A. Mariani, M. Bersani, C. Bonato, M. Basilico, M. Montorsi, E. Beretta

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The diagnostic role of serum and pancreatic juice CA 19-9 determination in discriminating surgically resectable pancreatic cancer from chronic pancreatitis was investigated. Only in about one third of cancer patients the serum assay was diagnostic versus subjects with chronic pancreatitis. None of 5 patients with 'early' pancreatic cancer had a diagnostic score [> 120 U/ml]. Conversely, the determination of CA 19-9 content in pure pancreatic juice, expressed as Units per microgram of protein, discriminated all the 15 patients with operable tumors, including those with early carcinoma, from subjects with chronic pancreatitis. The CA 19-9 assay of pancreatic juice is proposed as a reliable marker of cancer in those patients in whom the ERCP pattern is not definitive for malignancy.

Original languageEnglish
JournalInternational Journal of Pancreatology
Volume3
Issue numberSUPPL. 1
Publication statusPublished - 1988

Fingerprint

Pancreatic Juice
Chronic Pancreatitis
Pancreatic Neoplasms
Differential Diagnosis
Serum
Neoplasms
Endoscopic Retrograde Cholangiopancreatography
Carcinoma
Proteins

ASJC Scopus subject areas

  • Endocrinology
  • Gastroenterology
  • Oncology

Cite this

CA 19-9 in serum and pancreatic juice : Its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis. / Malesci, A.; Evangelista, A.; Mariani, A.; Bersani, M.; Bonato, C.; Basilico, M.; Montorsi, M.; Beretta, E.

In: International Journal of Pancreatology, Vol. 3, No. SUPPL. 1, 1988.

Research output: Contribution to journalArticle

@article{01dd9c608179481c9f2f728d290b07ce,
title = "CA 19-9 in serum and pancreatic juice: Its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis",
abstract = "The diagnostic role of serum and pancreatic juice CA 19-9 determination in discriminating surgically resectable pancreatic cancer from chronic pancreatitis was investigated. Only in about one third of cancer patients the serum assay was diagnostic versus subjects with chronic pancreatitis. None of 5 patients with 'early' pancreatic cancer had a diagnostic score [> 120 U/ml]. Conversely, the determination of CA 19-9 content in pure pancreatic juice, expressed as Units per microgram of protein, discriminated all the 15 patients with operable tumors, including those with early carcinoma, from subjects with chronic pancreatitis. The CA 19-9 assay of pancreatic juice is proposed as a reliable marker of cancer in those patients in whom the ERCP pattern is not definitive for malignancy.",
author = "A. Malesci and A. Evangelista and A. Mariani and M. Bersani and C. Bonato and M. Basilico and M. Montorsi and E. Beretta",
year = "1988",
language = "English",
volume = "3",
journal = "International Journal of Gastrointestinal Cancer",
issn = "1537-3649",
publisher = "Humana Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - CA 19-9 in serum and pancreatic juice

T2 - Its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis

AU - Malesci, A.

AU - Evangelista, A.

AU - Mariani, A.

AU - Bersani, M.

AU - Bonato, C.

AU - Basilico, M.

AU - Montorsi, M.

AU - Beretta, E.

PY - 1988

Y1 - 1988

N2 - The diagnostic role of serum and pancreatic juice CA 19-9 determination in discriminating surgically resectable pancreatic cancer from chronic pancreatitis was investigated. Only in about one third of cancer patients the serum assay was diagnostic versus subjects with chronic pancreatitis. None of 5 patients with 'early' pancreatic cancer had a diagnostic score [> 120 U/ml]. Conversely, the determination of CA 19-9 content in pure pancreatic juice, expressed as Units per microgram of protein, discriminated all the 15 patients with operable tumors, including those with early carcinoma, from subjects with chronic pancreatitis. The CA 19-9 assay of pancreatic juice is proposed as a reliable marker of cancer in those patients in whom the ERCP pattern is not definitive for malignancy.

AB - The diagnostic role of serum and pancreatic juice CA 19-9 determination in discriminating surgically resectable pancreatic cancer from chronic pancreatitis was investigated. Only in about one third of cancer patients the serum assay was diagnostic versus subjects with chronic pancreatitis. None of 5 patients with 'early' pancreatic cancer had a diagnostic score [> 120 U/ml]. Conversely, the determination of CA 19-9 content in pure pancreatic juice, expressed as Units per microgram of protein, discriminated all the 15 patients with operable tumors, including those with early carcinoma, from subjects with chronic pancreatitis. The CA 19-9 assay of pancreatic juice is proposed as a reliable marker of cancer in those patients in whom the ERCP pattern is not definitive for malignancy.

UR - http://www.scopus.com/inward/record.url?scp=0023948903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023948903&partnerID=8YFLogxK

M3 - Article

C2 - 3209865

AN - SCOPUS:0023948903

VL - 3

JO - International Journal of Gastrointestinal Cancer

JF - International Journal of Gastrointestinal Cancer

SN - 1537-3649

IS - SUPPL. 1

ER -